The University of Chicago

Max-planck-gesellschaft Zur F&#xf6;rderung Der Wissenschaften E. V.

Ernst Lengyel

Matthias Mann

Fabian Coscia

Marion Curtis

Anthony A Kossiakoff

Joseph Piccirilli

Kristin Nieman

Hilary Kenny

The current disclosure relates to methods for treating ovarian cancer based on specific antigen expression of the cancer. Furthermore, the expressed antigen may be used in immunotherapeutic methods for treatment of the ovarian cancer. Aspects of the disclosure relate to immunotherapies targeting CT45 polypeptides, methods for treating ovarian cancer based on CT45 expression, and kits for detecting CT45 polypeptides and nucleotides.

Methods of treating cancers with CT45 targeted therapies

Compositions and methods for delivering an agent to a cell comprising a prolactin receptor are provided. Also provided is a method of inhibiting a breast, ovarian or prostate cancer cell, where the method includes a step of contacting the cell with a complex comprising a prolactin receptor ligand linked to at least one of an RNAi-inducing agent, a polynucleotide sequence encoding a polypeptide, an miRNA, a cytotoxic moiety, a chemotherapeutic moiety, a radioactive moiety or a nanoparticle. Methods of detecting a cancer cell expressing a prolactin receptor are also provided.

Receptor-mediated delivery: compositions and methods

The present invention concerns methods and compositions for the inhibition or reduction of the primary tumor and metastasis by inhibition of fatty acid binding proteins.

Methods for treating ovarian cancer by inhibiting fatty acid binding proteins

Growing community of inventors

Chicago, IL, United States of America

Ernst Lengyel